Of interest, NPM1-mutated AML patients who obtain long-term MRD-negative CR, but returning to a clonal hematopoiesis status, e.g., with persistent DNMT3A gene mutation, could be predisposed to development of a second different myeloid neoplasm. This evidence concerns the gene DNMT3A and acute myeloid leukemia.